The Top 5 Biosimilars Articles for the Week of November 4

The Center for Biosimilars® recaps the top stories for the week of November 4, 2019.
November 08, 2019


Transcript

Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of November 4, 2019.

Number 5: The biggest cost difference in filgrastim administrations was seen in the commercially insured population after the launch of a biosimilar, according to a new study.

Number 4: The FDA has issued an establishment inspection report for Biocon’s biosimilars facility, and the company says that it plans to launch its trastuzumab biosimilar soon.

Number 3: Samsung Bioepis has entered into a new commercialization agreement with Biogen for 2 ophthalmology biosimilars.   

Number 2: Effective January 1, 2020, UnitedHealthcare patients who are receiving the reference epoetin alfa will be required to switch to Pfizer’s biosimilar.

Number 1: At the end of a lengthy regulatory road for Sandoz, the FDA approved the company’s biosimilar pegfilgrastim referencing Neulasta.

Finally, our e-newsletter asked whether you think that enacting legislation to create a CMS star ratings system based on biosimilar availability would help improve biosimilar uptake.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.
 

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.